Night Surge Pen – CJC-1295 No DAC + Ipamorelin 10mg

The Night Surge Pen combines CJC-1295 No DAC and Ipamorelin in a convenient 2.6 mL pre-filled peptide pen. Each pen contains 10 mg total active peptides, 5 mg CJC-1295 No DAC + 5 mg Ipamorelin, delivered through 240 precision clicks.

The combination is researched for its interaction with pathways involved in growth hormone signalling, nocturnal GH release, sleep-associated recovery, muscle recovery and body composition.

Key Features

• 10 mg total peptide blend
• 5 mg CJC-1295 No DAC + 5 mg Ipamorelin
• 2.6 mL pre-filled peptide pen
• 240 precision clicks
• Approximately 41.7 mcg total peptide blend per click
• 10 clicks ≈ 400 mcg total blend
• 12 clicks ≈ 500 mcg total blend
• Supplied with 6 sterile needles
• Research interest in growth hormone signalling and nocturnal GH pathways
• Convenient multi-dose format
• Precision MSSPT peptide pen technology

About CJC-1295 No DAC + Ipamorelin

CJC-1295 No DAC is a modified growth hormone-releasing hormone (GHRH) analogue researched for its interaction with GHRH receptors and its potential to influence endogenous growth hormone release.

Ipamorelin is a selective growth hormone secretagogue researched for its interaction with the ghrelin receptor (GHSR-1a) and stimulation of growth hormone release.

The combination has attracted research interest because it targets complementary pathways involved in GH signalling and pulsatile secretion. Night-time use is particularly associated with research protocols investigating the relationship between growth hormone release, sleep and recovery.

Research Areas

Research involving CJC-1295 and Ipamorelin has explored their potential relationship with:

• Growth hormone signalling
• Nocturnal GH secretion
• Sleep-associated recovery
• Muscle and connective-tissue recovery
• Protein synthesis and tissue remodelling
• Metabolic and body-composition pathways
• Age-related changes in GH signalling

These represent areas of research interest and should not be interpreted as established medical indications or treatment claims.

Research Dosage Protocol

The following information is the manufacturer-supplied research protocol and is provided for research reference only. It is not a recommendation or instruction for human use.

Standard research dose range:

• 400–500 mcg total peptide blend per administration
• 400 mcg: approximately 10 clicks
• 500 mcg: approximately 12 clicks
• Each dose provides approximately equal quantities of CJC-1295 No DAC and Ipamorelin

Frequency described in the supplied protocol:

• Once daily
• 5–7 evenings per week
• Example research schedule: 5 days on / 2 days off

Timing: The supplied protocol specifies evening/bedtime administration, approximately 1–2 hours after the last meal.

Research cycle: 8–16 weeks, with approximately 12 weeks described for sustained research protocols, followed by a 4-week break.

Click conversion: approximately 41.7 mcg total peptide blend per click.

Precision Peptide Pen Technology

The Night Surge Pen incorporates MSSPT (Molecular Stabilisation and Storage Protection Technology), designed to support formulation stability against environmental factors including light, oxygen, moisture and temperature fluctuations.

The pre-filled multi-dose format provides convenient click-based measurement without conventional reconstitution.

Storage & Handling

• Store according to the manufacturer’s recommended storage conditions.
• Refrigerate where specified and never freeze.
• If stored outside refrigeration, keep in a cool, dry environment within the recommended temperature range.
• Keep the pen capped and protected from direct light and excessive heat.
• Keep out of reach of children.
• Do not use if the solution is cloudy, discoloured or contains visible particles.
• Discard expired or visibly compromised product appropriately.

Research & Safety Information

Night Surge Pen is supplied by Lekker Peptides for research purposes only. CJC-1295 No DAC and Ipamorelin are investigational peptide compounds in this context and should not be represented as approved treatments for sleep, ageing, metabolic conditions, recovery or body composition.

The product is not intended to diagnose, treat, cure or prevent any disease. Statements have not been evaluated or approved by SAHPRA, the FDA or other regulatory authorities for the uses described above.

Growth hormone secretagogues may have physiological effects on the GH/IGF-1 axis, glucose metabolism and fluid balance. Research involving these compounds should be conducted with appropriate professional oversight.

For research use only. Not for human consumption.